Brief: GSK, Iteos Collaborate For EOS-448, Iteo To Get $625 Mln Upfront Payment

iTeos Therapeutics

14/06/2021 12:05

June 14 (Reuters) - GlaxoSmithKline PLC  GSK.L :
    * GLAXOSMITHKLINE PLC  - GSK AND ITEOS ANNOUNCE
COLLABORATION FOR
EOS-448
    * GSK - EOS-448 IS CURRENTLY IN PHASE I FOR ADVANCED SOLID
TUMOURS
WITH A RANDOMISED PD-1 COMBINATION STUDY PLANNED FOR 2022
    * GSK - ITEOS TO RECEIVE A $625 MILLION UPFRONT PAYMENT IN
ADDITION TO POTENTIAL MILESTONES, AND ROYALTY PAYMENTS ON EX-US
SALES
    * GSK -
    * GSK - GSK AND ITEOS WILL CO-COMMERCIALISE AND SHARE
PROFITS IN
US
    * GSK - GSK NOW HAS LEADING PORTFOLIO OF ANTIBODIES
TARGETING
CD226 AXIS - A KEY TARGET FOR NEXT-GENERATION IMMUNO-ONCOLOGY
THERAPIES
    * GSK - WITH THIS COLLABORATION GSK IS UNIQUELY POSITIONED
WITH
ACCESS TO ANTIBODIES THAT SYNERGISTICALLY TARGET ALL THREE KNOWN
CD226 CHECKPOINTS
    * GSK - ITEOS WILL BE ELIGIBLE TO RECEIVE UP TO AN
ADDITIONAL
$1.45 BILLION IN MILESTONE PAYMENTS, SHOULD EOS-448 PROGRAMME
ACHIEVE CERTAIN MILESTONES
    * GSK - WITHIN COLLABORATION, GSK AND ITEOS WILL SHARE
RESPONSIBILITY AND COSTS FOR GLOBAL DEVELOPMENT OF EOS-448
    * GSK - EXPECTS TO SUBMIT AN INVESTIGATIONAL NEW DRUG
APPLICATION
FOR GSK'562 (ANTI-PVRIG IN-LICENSED AS SRF-813 FROM SURFACE
ONCOLOGY) BY MID-2022
    * GSK - GSK AND ITEOS PLAN TO START COMBINATION STUDIES OF
EOS-448
WITH DOSTARLIMAB IN 2022

Source text for Eikon:  ID:nRSN7779Ba 
Further company coverage:  GSK.L 

 ((Reuters.Briefs@thomsonreuters.com;))